This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should iShares S&P Small-Cap 600 Growth ETF (IJT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJT
PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study
by Zacks Equity Research
Pacira doses the first patient in the phase II ASCEND study of PCRX-201 gene therapy for OA of the knee.
DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up
by Zacks Equity Research
Denali stock up as it begins rolling BLA submission with the FDA for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome.
NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program
by Zacks Equity Research
Nurix stock gains as SNY expands its partnership, licensing a research program targeting a previously untreatable transcription factor for autoimmune diseases.
Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More
by Ekta Bagri
CORT and AXSM are in the spotlight this week following the announcement of study data.
Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag
by Zacks Equity Research
The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.
CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal
by Zacks Equity Research
The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian cancer meets the primary endpoint.
Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar?
by Zacks Equity Research
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States
by Zacks Equity Research
The FDA approves Sanofi's Qfitlia as the first therapy in the United States to treat hemophilia A or B with or without inhibitors.
AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication
by Zacks Equity Research
The FDA approves AZN's sBLA seeking the expanded use of Imfinzi for adult patients with muscle-invasive bladder cancer.
Here's Why Momentum in Corcept (CORT) Should Keep going
by Zacks Equity Research
Corcept (CORT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
KOD reports a narrower-than-expected loss for the fourth quarter of 2024. The company provides updates regarding its pipeline development plans.
PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know
by Zacks Equity Research
Pliant stock crashes 89% in three months following setbacks in the mid-stage study of its lead candidate, bexotegrast, for idiopathic pulmonary fibrosis.
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
by Zacks Equity Research
Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating hyperphagia in PWS patients.
Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Corcept Therapeutics (CORT) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies
by Zacks Equity Research
AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or immune-mediated diseases.
NVO Stock Down 9% as CagriSema Misses Target in Second Obesity Study
by Zacks Equity Research
Novo Nordisk stock slumps as the 15.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in the second phase III study, missing the guidance of 25%.
KOD Completes Enrollment in Phase III Study for Eye Disease Candidate
by Zacks Equity Research
Kodiak reports completing patient enrollment in its late-stage study evaluating tarcocimab for diabetic retinopathy.
Is First Trust Mid Cap Growth AlphaDEX ETF (FNY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FNY
INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies
by Zacks Equity Research
Incyte reports positive data from two phase III studies evaluating Opzelura for prurigo nodularis in adults.
Corcept Shares Rise More Than 55% in 6 Months: Here's Why
by Zacks Equity Research
CORT's Cushing's syndrome drug, Korlym, is driving revenues. The FDA's acceptance of the NDA for relacorilant also bodes well.
Are Options Traders Betting on a Big Move in Corcept Therapeutics (CORT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Corcept Therapeutics (CORT) stock based on the movements in the options market lately.
3 Reasons Why Growth Investors Shouldn't Overlook Corcept (CORT)
by Zacks Equity Research
Corcept (CORT) possesses solid growth attributes, which could help it handily outperform the market.